A detailed history of D. E. Shaw & Co., Inc. transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 56,841 shares of FLGT stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,841
Holding current value
$1.02 Million
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.6 - $25.06 $1.48 Million - $1.89 Million
-75,503 Reduced 57.05%
56,841 $1.23 Million
Q2 2024

Aug 14, 2024

SELL
$19.09 - $22.57 $49,328 - $58,320
-2,584 Reduced 1.92%
132,344 $2.6 Million
Q1 2024

May 15, 2024

BUY
$21.55 - $29.29 $2.03 Million - $2.76 Million
94,233 Added 231.56%
134,928 $2.93 Million
Q4 2023

Feb 14, 2024

SELL
$23.64 - $30.27 $60,234 - $77,127
-2,548 Reduced 5.89%
40,695 $1.18 Million
Q3 2023

Nov 14, 2023

SELL
$26.74 - $40.81 $36,099 - $55,093
-1,350 Reduced 3.03%
43,243 $1.16 Million
Q2 2023

Aug 14, 2023

SELL
$28.52 - $40.7 $981,059 - $1.4 Million
-34,399 Reduced 43.55%
44,593 $1.65 Million
Q1 2023

May 15, 2023

BUY
$29.39 - $36.27 $1.25 Million - $1.54 Million
42,496 Added 116.44%
78,992 $2.47 Million
Q4 2022

Feb 14, 2023

BUY
$29.23 - $40.28 $293,059 - $403,847
10,026 Added 37.88%
36,496 $1.09 Million
Q3 2022

Nov 14, 2022

BUY
$37.92 - $63.74 $222,590 - $374,153
5,870 Added 28.5%
26,470 $1.01 Million
Q2 2022

Aug 15, 2022

BUY
$47.98 - $62.75 $427,022 - $558,475
8,900 Added 76.07%
20,600 $1.12 Million
Q1 2022

May 16, 2022

BUY
$49.85 - $96.11 $583,245 - $1.12 Million
11,700 New
11,700 $730,000
Q2 2021

Aug 16, 2021

SELL
$66.8 - $100.45 $394,454 - $593,157
-5,905 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$59.3 - $183.85 $350,166 - $1.09 Million
5,905 New
5,905 $571,000

Others Institutions Holding FLGT

About Fulgent Genetics, Inc.


  • Ticker FLGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,265,800
  • Market Cap $541M
  • Description
  • Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...
More about FLGT
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.